Angiogenesis 2023: Efficacy and safety of high-dose aflibercept for treatment of DME
February 28th 2023David S. Boyer, MD, presented data from the PHOTON study examining the safety and efficacy of high-dose aflibercept for treatment of diabetic macular edema at the 2023 Angiogenesis, Exudation, and Degeneration conference.
Read More
The importance of ocular health prior to cataract and refractive surgery
February 28th 2023Dr. Jai Parekh, a clinical associate professor of Ophthalmology/The New York Eye & Infirmary of the Mount Sinai School of Medicine and David Hutton, Managing Editor of Opthalmology Times discuss the importance of ocular health prior to cataract and refractive surgery, specifically with osmolarity testing.
Read More
Glaukos submits New Drug Application to FDA for micro-invasive intraocular implant
February 27th 2023The company’s iDose TR is a micro-invasive intraocular implant designed to continuously deliver therapeutic levels of a proprietary formulation of travoprost from within the eye for extended periods of time.
Read More
A sight for sore eyes: Anti-VEGF treatment studied in ocular model of viral infection
February 27th 2023Researchers from Tokyo Medical and Dental University evaluated the safety of an anti-VEGF drug, aflibercept, in a cell culture model exposed to human T-cell lymphotropic virus type 1, which is known to cause a number of diseases, including inflammatory diseases of the eye.
Read More
FDA accepts aflibercept 8 mg BLA for treatment of wet AMD and DME for priority review
February 23rd 2023According to Regeneron, the BLA is supported by two pivotal trials demonstrating non-inferior vision gains to aflibercept injection, with a majority of patients maintaining extended dosing regimens through 48 weeks.
Read More
EnVision Summit 2023: Surgical curriculum for ophthalmology residents
February 18th 2023At the EnVision Summit Ophthalmology in Puerto Rico, Grace Sun, MD, made a presentation titled "Surgical Curriculum for Ophthalmology Residents" to train them to be competent in a broad range of basic and advanced surgical skills.
Read More
EnVision Summit 2023: Comanagement of AMD, DME and CME in the setting of cataract surgery
February 18th 2023During the EnVision Summit Ophthalmology in Puerto Rico, Victor Villegas, MD, made a presentation titled "From a Retina Perspective: Comanagement of AMD, DME and CME in the Setting of Cataract Surgery," focusing on how to comanage patients that have macular degeneration, diabetic maculopathy and cystoid macular edema.
Read More
Formosa Pharmaceuticals announces development collaboration agreement with Eyenovia
February 15th 2023According to the companies, the collaboration will combine Formosa's APNT nanoparticle formulation platform with Eyenovia's Optejet dispensing technology for the development of new ophthalmic therapies in indications with significant unmet medical needs.
Read More
FDA accepts NDA, sets PDUFA date for Ocuphire Pharma’s mydriasis treatment
February 13th 2023If approved later this year, phentolamine ophthalmic solution 0.75% could be the only commercially available eye drop for the reversal of dilation. It is being developed for reversal of pharmacologically-induced mydriasis, presbyopia, and dim light vision disturbances under the 505(b)(2) pathway.
Read More
Ellipsoid zone integrity in dry AMD focus of presentation at Angiogenesis 2023
February 10th 2023In a presentation at the Angiogenesis, Exudation, and Degeneration 2023 conference, Justis Ehlers, MD, presented "Ellipsoid Zone Integrity in Dry AMD: An Imaging Biomarker for Progression Risk and Clinical Trial Endpoint.”
Read More